Albumindialysis in Acute Pancreatitis (pancreatitis)

This study has suspended participant recruitment.
Sponsor:
Information provided by:
University of Tampere
ClinicalTrials.gov Identifier:
NCT00483912
First received: June 7, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
  Purpose

The incidence of acute pancreatitis has been doubled during last three decades in Finland. Alcohol is the main cause of acute pancreatitis in Finland accounting for 70 % of cases. Although the mortality of acute pancreatitis has been decreased it still appears and especially early multiple organ failure is the main cause of all deaths. Multiple organ failure in the early course of the disease is thought to be caused by the release of cytokines. Molecular adsorbent recirculating system (MARS) has shown to decrease mortality in acute alcohol hepatitis and paracetamol intoxication. Also it has been shown to improve kidney function due to hypoperfusion and tubulus necrosis and overrule decrease mortality in patients with multiple organ failure due to different reasons. A part of patients with acute alcoholic pancreatitis may have so-called fat liver already on admission. It has been shown that the highest mortality is especially associated those with early liver and kidney failure. MARS treatment has never earlier been used in the patients with acute alcoholic pancreatitis and early organ failure. In this study we randomize patients with acute alcoholic pancreatitis and early multiple organ failure (Sofa score>2) to two groups: 1) Standard pancreatitis treatment in intensive care unit and 2) Standard pancreatitis treatment in intensive care unit with 5 MARS sessions.


Condition Intervention
Pancreatitis
Multiple Organ Failure
Device: Molecular adsorbent recirculating system

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Official Title: Molecular Adsorbent Recirculating System (MARS) in Severe Acute Pancreatitis

Resource links provided by NLM:


Further study details as provided by University of Tampere:

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Severe acute alcoholic pancreatitis with early multiple organ failure (Sofa score >2)

Exclusion Criteria:

  • If patient or his/her family member refuses, pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00483912

Locations
Finland
Tampere University Hospital
Tampere, Finland, 33521
Sponsors and Collaborators
University of Tampere
Investigators
Study Chair: Sari Räty Dept. of Gastroenterology and Alimentary Tract Surgery
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00483912     History of Changes
Other Study ID Numbers: R04005
Study First Received: June 7, 2007
Last Updated: June 7, 2007
Health Authority: Finland: Social and Heath Ministry

Keywords provided by University of Tampere:
pancreatitis, MARS
severe acute pancreatitis with early multiple organ failure

Additional relevant MeSH terms:
Multiple Organ Failure
Pancreatitis
Digestive System Diseases
Pancreatic Diseases
Pathologic Processes
Shock

ClinicalTrials.gov processed this record on October 20, 2014